<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="308210">
  <stage>Registered</stage>
  <submitdate>21/08/2009</submitdate>
  <approvaldate>25/08/2009</approvaldate>
  <actrnumber>ACTRN12609000731291</actrnumber>
  <trial_identification>
    <studytitle>the use of dexmedetomidine as an analgesic after uvulopalatopharyngoplasty for obstructive sleep apnea.</studytitle>
    <scientifictitle>analgesic and sedative properties of dexmedetomidine infusion after uvulopalatopharyngoplasty for obstructive sleep apnea.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>obstructive sleep apnea</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Sleep apnoea</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Anaesthesiology</conditioncode1>
      <conditioncode2>Anaesthetics</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>dexmedetomidine loading dose:1 microgram /kg.intravenous infusion over 20min;this was administered 30 min before the suspected end of surgery
infusion dose:0.6 microgram /kg / h.following the loading infusion and continued till the end of the first postoperative day</interventions>
    <comparator>placebo: normal saline infusion; as a loading dose; 30 min before the suspected end of surgery, followed by continous intravenous infusion, with the same infusion 's rate as the testing drug.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>postoperative visual analogue pain score</outcome>
      <timepoint>Pain scores were recorded using a VAS scale every 30 min during the first 2 h, every 60 min during the next 10 h and every 4 h during the next 36 hours postoperatively</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>postoperative morphine consumption by patient-controlled analgesia</outcome>
      <timepoint>at 12,24,36,48h postoperative.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>postoperative morphine side effects.Most common morphine side effects are nausea and vomiting.The presence of nausea and vomiting was noted(by clinical observation of the patients) using a four-point scale (0=no nausea or vomiting, 1=mild nausea, 2=sever nausea, 3=retching or vomiting).</outcome>
      <timepoint>24h postoperative.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>postoperative satisfaction score</outcome>
      <timepoint>24h postoperative.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-frequent loud snoring and arousal from sleep.
-apnea-hypopnea index 20-40.</inclusivecriteria>
    <inclusiveminage>38</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>55</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-history of ischemic heart disease.
-long term use of certain medications(beta blockers, sedative and analgesics).</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>randomization was carried out by computer generated codes.The codes were maintained in sequentially numbered, opaque envelopes, which were opened before induction of anesthesia.</concealment>
    <sequence>randomization was carried out by computer generated codes. The codes were maintained in sequentially numbered, opaque envelopes, which were opened before induction of anesthesia.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>11/07/2007</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>39</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Saudi Arabia</country>
      <state>eastern</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr.walid Abd El Mageed</primarysponsorname>
    <primarysponsoraddress>king abdullaziz naval base, jubail 31951.
P.O.Box 413</primarysponsoraddress>
    <primarysponsorcountry>Saudi Arabia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>King Abdullaziz Naval Base Hospital</fundingname>
      <fundingaddress>king abdullaziz naval base, jubail 31951.
P.O.Box413</fundingaddress>
      <fundingcountry>Saudi Arabia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Dr.Ahmad Nassar</sponsorname>
      <sponsoraddress>king abdullaziz naval base, jubail 31951.
P.O.Box413</sponsoraddress>
      <sponsorcountry>Saudi Arabia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Dexmedetomidine is an alpha2- adrenergic agonist with sedative and analgesic properties. This study aimed to investigate if the use of continuous dexmedetomidine infusion with i.v. morphine patient-controlled analgesia (PCA) could improve postoperative analgesia while reducing opioid consumption and opioid-related side effects.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Hospital Ethics Committee</ethicname>
      <ethicaddress>king abdullaziz naval base hospital , jubail 31951.
P.O.Box413</ethicaddress>
      <ethicapprovaldate>25/05/2007</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>24/04/2007</ethicsubmitdate>
      <ethiccountry>Saudi Arabia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr.Walid Abd El Mageed</name>
      <address>King Abdullaziz Naval Base Hospital, Jubail 31951.P.O.Box :413</address>
      <phone>+966 557189366</phone>
      <fax />
      <email>walidabdelmageed@yahoo.com</email>
      <country>Saudi Arabia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr.Walid Abd El Mageed</name>
      <address>King Abdullaziz Naval Base Hospital, Jubail 31951.P.O.Box :413</address>
      <phone>+966 557189366</phone>
      <fax />
      <email>walidabdelmageed@yahoo.com</email>
      <country>Saudi Arabia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr. Ahmad Nassar</name>
      <address>King Abdullaziz Naval Base Hospital, Jubail 31951.P.O.Box :413</address>
      <phone>+966 508435430</phone>
      <fax />
      <email>ahmedinassar@hotmail.com</email>
      <country>Saudi Arabia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>